
Korea is a great entry market in Asia: It has a high quality health care system with large hospitals that can run complex clinical trials and recruit a lot of patients in a short time. Participating to the Swiss-Korean Innovation Week 2019, we networked mostly with investors and hospitals. As a result, a Korean investor invested in hemotune last year, of course further strengthening the relationship to Korea.
Lukas Langenegger CEO, hemotune